U.S. markets closed

ChromaDex Corporation (CDXC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.04+0.06 (+0.67%)
At close: 4:00PM EDT

9.06 +0.02 (0.22%)
After hours: 7:39PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close8.98
Open8.92
Bid8.86 x 900
Ask9.06 x 2200
Day's Range8.74 - 9.37
52 Week Range3.41 - 23.66
Volume750,009
Avg. Volume3,895,185
Market Cap603.486M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateMar 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
    Business Wire

    ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency

    ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program (CERP™) and leading research institutions, the Citrin Foundation will fund a series of preclinical and clinical studies to explore the potential impact of increased NAD+ levels on patients with citrin deficiency. The first study, led by Prof. Paul M. Yen and other scientists at Duke-NUS Medical School in Singapore, will examine the ability of NR to impact mitochondrial function, lipid accumulation, inflammation, and fibrosis in the liver using preclinical models of citrin deficiency.

  • Is Now An Opportune Moment To Examine ChromaDex Corporation (NASDAQ:CDXC)?
    Simply Wall St.

    Is Now An Opportune Moment To Examine ChromaDex Corporation (NASDAQ:CDXC)?

    ChromaDex Corporation ( NASDAQ:CDXC ), is not the largest company out there, but it led the NASDAQCM gainers with a...

  • ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference
    Business Wire

    ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference

    ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021 Investor Conference.